{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-1UU2RF4H/cb1d42d9-bf7e-4c8e-a2fe-535c214ad053/HTML","dcterms:extent":"24 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-1UU2RF4H/7eab2292-ec8c-4c1d-bfae-b6222cbec9fc/PDF","dcterms:extent":"697 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-1UU2RF4H/ff82a163-c472-464a-b4d6-aad61a91bbe4/TEXT","dcterms:extent":"23 KB"}],"edm:TimeSpan":{"@rdf:about":"2002-2026","edm:begin":{"@xml:lang":"en","#text":"2002"},"edm:end":{"@xml:lang":"en","#text":"2026"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:DOC-1UU2RF4H","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/urn:nbn:si:spr-py0w57lr"},{"@xml:lang":"sl","#text":"Zdravstveno varstvo"}],"dcterms:issued":"2006","dc:creator":["Iljaž, Rade","Kramar, Milka"],"dc:format":[{"@xml:lang":"sl","#text":"številka:1"},{"@xml:lang":"sl","#text":"letnik:45"},{"@xml:lang":"sl","#text":"9 strani"},{"@xml:lang":"sl","#text":"str. 23-31"}],"dc:identifier":["ISSN:0351-0026","COBISSID:20962265","URN:URN:NBN:SI:doc-1UU2RF4H"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Inštitut za varovanje zdravja Republike Slovenije"},"dc:subject":[{"@xml:lang":"en","#text":"(RS)-methadones"},{"@xml:lang":"en","#text":"Age Factors"},{"@xml:lang":"sl","#text":"droge"},{"@xml:lang":"en","#text":"Drug Therapy"},{"@xml:lang":"sl","#text":"Metadon"},{"@xml:lang":"en","#text":"Methadone"},{"@xml:lang":"sl","#text":"Psihoterapija"},{"@xml:lang":"en","#text":"Psychotherapy"},{"@xml:lang":"en","#text":"Sex Factors"},{"@xml:lang":"sl","#text":"Snov, zloraba, centri za zdravljenje"},{"@xml:lang":"sl","#text":"Spolni faktorji"},{"@xml:lang":"sl","#text":"Starostni faktorji"},{"@xml:lang":"en","#text":"Substance Abuse Treatment Centers"},{"@xml:lang":"en","#text":"Substance Dependence"},{"@xml:lang":"sl","#text":"vzdrževalno zdravljenje"},{"@xml:lang":"sl","#text":"zasvojenost"}],"dcterms:temporal":{"@rdf:resource":"2002-2026"},"dc:title":{"@xml:lang":"sl","#text":"Ali lahko napovemo čas vzdrževalnega zdravljenja z metadonom?| Can we predict tenure in methadone maintance treatment?| initial ten years of services provided by the Bre ice Centre for prevention and treatment of illicit drug addiction| pregled 10-letnega dela Centra za preprečevanje in zdravljenje odvisnosti od prepovedanih drog (CPOZD) Brežice|"},"dc:description":[{"@xml:lang":"sl","#text":"Introduction: The Brežice Center for Prevention and Treatment of Illicit Drug Addiction (CPTIDA) was established in 1995 as part of the original network of such centres in Slovenia. The Brežice Centre employs a physician and a graduate nurse on a part-time basis. Methods: A retrospective study of the initial ten years of services provided in the Brežice Centre, and a comparisonof key indicators by age, gender and type of therapeutic intervention. The purpose of the study was to determine significant treatment predictors of tenure in methadone maintenance programme. Results: In the initial ten years of its existence, the Brežice Centre provided treatment to 205 Slovene citizens.Ninety-three of them, 68 men and 25 women, were included in the methadone maintenance programme, while others received psychological orpsychiatric interventions as aprt of the psychosocial programme. The averageage at first visit to the Centre was 21.8 years (1.9 years in psychosocial programme vs. 24 years in methadone maintenance programme). The one-way ANOVA revealed statistically significant differences in the average age of entrants to the psychosocial counselling programme depending on the type of illicit drug used (opiate, cannabis and benzodiazepines). The highest average dose and the highest initial dose of methadone were found to be statistically significant predictors of average tenure in methadone maintenance. Conclusion: The highest initial dose and the highest average doseof methadone are the factors to be considered when predicting methadone treatment tenure. The average age of programme entrants has no impact on the average tenure in methadone treatment"},{"@xml:lang":"sl","#text":"Uvod: Center za prevencijo in zdravljenje odvisnosti od prepovedanih drog (CPZOD) v Brežicah je začel svoje delo leta 1995 kot del prvotne mreže tovrstnih centrov v Sloveniji. V centru sta za del delovnega časa stalno zaposlena zdravnik in diplomirana medicinska sestra. Metode: Retrospektivna študija 10 let dela CPZOD Brežice, s primerjavo kazalcev dela po starosti in spolu in obliki ukrepa ter iskanje napovednih dejavnikov za čas zdravljenja v vzdrževalnem metadonskem programu (VMP) Centra. Rezultati: V prvih 10 letih dela je v CPZOD Brežice bilo obravnavanih 205 državljanov republike Slovenije.93 jih je bilo vključenih v t.i. vzdrževalno metadonsko zdravljenje (VMZ), od tega 68 moških in 25 žensk. Ostale je obravnavala psihologinja in psihiater oz. so bili deležni psihosocialnih ukrepov. Povprečna starost ob prvem obisku centra je bila 21,8 let, in sicer 19,9 let za psihosocialno svetovanje in 24 let za vzdrževalno metadonsko zdravljenje. Z enosmerno analizo variance (ANOVA), smo ugotovili statistično značilne razlike glede povprečne starosti pri psihosocialnem svetovanju zaradi treh različnih prepovedanih drog (opiati, benzodiazepini in kanabis). Z uporabo multivariatneanalize smo kot statistično značilne napovedne dejavnike za čas zdravljenja v vzdrževalnem metadonskem programu potrdili povprečni in začetni najvišji odmerek metadona. Zaključek: Pri napovedovanju časa vzdrževalnega zdravljenja z metadonom velja upoštevati največji začetni in skupni odmerek metadona. Starost ob začetku zdravljenja pa načeloma nima pojasnjevalnega učinka pri napovedovanju časa vzdrževalnega zdravljenja z metadonom"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:DOC-1UU2RF4H","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:DOC-1UU2RF4H"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:DOC-1UU2RF4H/7eab2292-ec8c-4c1d-bfae-b6222cbec9fc/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Inštitut za varovanje zdravja RS"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:DOC-1UU2RF4H/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:DOC-1UU2RF4H"}}}}